Original Article

Prognostic significance of cancer stem cell marker CD133 expression in breast cancer

Linjun Han¹, Xianshu Gao², Xiaobin Gu², Wei Guo¹, Mingwei Ma², Xin Qi², Ming Cui², Mu Xie², Yun Bai², Chuan Peng², Xiaoying Li²

¹Hebei North University, Zhangjiakou, Hebei, China; ²Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China

Received December 13, 2016; Accepted January 19, 2017; Epub March 15, 2017; Published March 30, 2017

Abstract: CD133 has been commonly used as a cancer stem cell (CSC) marker in breast cancer. However, the correlation between CD133 expression, and clinicopathological characteristics and prognosis in breast cancer, remains inconsistent. This study was designed to explore the relationship between CD133 and clinicopathological characteristics, as well as overall survival (OS), through meta-analysis. An electronic search was conducted utilizing the databases of PubMed, Embase, and the Web of Science, up to October 21, 2016. Pooled odds ratios (ORs), and hazard ratios (HRs) with 95% confidence intervals (CIs), were calculated. Publication bias was estimated using Begg’s test and Egger’s test. A total of 11 studies involving 1447 patients were included in this meta-analysis. The data showed that CD133 expression was correlated with a G3 tumor grade (OR=1.82, 95% CI=1.4-2.36, P<0.001), the presence of lymph node metastasis (OR=2.21, 95% CI=1.75-2.79, P<0.001), negative PR status (OR=0.62, 95% CI=0.47-0.81, P=0.001), negative ER status (OR=0.4, 95% CI=0.19-0.86, P=0.018), advanced TNM stage (OR=2.74, 95% CI=2.05-3.66, P<0.001) and positive HER2 status (OR=2.00, 95% CI=1.04-3.85, P=0.039). Furthermore, CD133 expression was correlated with poor OS (HR=2.04, 95% CI=1.32-3.14, P<0.001). There was no significant publication bias in this meta-analysis. The present meta-analysis demonstrated that CD133 expression was correlated with several clinicopathological characteristics and a poor prognosis. CD133 can be considered as an effective tool for pathological diagnosis and prognostic prediction in breast cancer.

Keywords: Meta-analysis, CD133, breast cancer, risk factors

Introduction

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer related death in women worldwide [1]. Breast cancer poses a severe threat to women’s health, both in developed countries and in developing countries [1]. Over the past several decades, advances in surgical techniques and targeted therapy for this disease have occurred; however, the prognosis of breast cancer remains unsatisfactory [2]. A variety of prognostic factors, including TNM stage, estrogen receptor (ER) status, and histological grade, are proposed and implemented in clinical practice [3]. Unfortunately, these biomarkers provide limited prognostic value, and lack accuracy. Therefore, more reliable and efficient prognostic factors for breast cancer are required, in order to stratify high-risk populations.

Accumulating evidence demonstrates that cancer stem cells (CSCs) could play important roles in tumor initiation, occurrence, and metastasis [4]. Various markers are commonly used to identify CSCs, such as CD34, CD38, CD44, CD133, and ALDH [4]. CD133, also known as prominin-1, is a trans-membrane glycoprotein expressed in various malignancies, including brain tumors [5], pancreatic cancer [6], non-small cell lung cancer [7], hepatocellular carcinoma [8], and ovarian cancer [9]. In recent years, a number of studies [10-20] also investigated the relationship between CD133 and the prognosis for breast cancer, but the results obtained were inconsistent. Such discrepancies might be due to different research methods, and differences between study populations. Therefore, we performed a quantitative meta-analysis to clarify the relationship between CD133 expression, clinicopathological
CD133 and breast cancer

characteristics, and the prognosis for breast cancer.

Materials and methods

Literature search

This study was designed and carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [21]. The databases of PubMed, Embase, and the Web of Science were thoroughly searched up to October 21, 2016. The following search terms were used: “CD133”, “prominin-1”, “AC133”, “breast cancer”, “breast carcinoma”, and “breast neoplasms” [MeSH Terms]. Moreover, reference lists of relevant original articles were manually searched for additional studies.

Selection criteria

The inclusion criteria were: (1) the diagnosis of breast cancer was based on pathological examination; (2) CD133 expression was detected using immunohistochemical staining (IHC); (3) studies reported the association between CD133 and overall survival (OS) and/or clinicopathological features, or the data of OS could be calculated using Parmar’s method [22]; (4) studies were published in English or Chinese; and (5) if multiple studies were conducted on the same patient population, the most comprehensive study was selected. The exclusion criteria were: (1) studies with insufficient data; (2) reviews, meeting abstracts, case reports, and letters; and (3) duplicated studies.

Quality assessment and data extraction

Quality of included studies was assessed using the Newcastle-Ottawa Scale (NOS) [23]. The scale evaluates studies across three dimensions: selection, comparability, and outcome. The maximum score is 9, and studies with a score ≥6 were considered high quality studies. Two researchers (LJH and XBG) independently extracted data from the eligible studies. The extracted data comprised first author, publication year, country, age of patients, sample size, detection method, TNM stage, research period, and percent of samples positive for CD133. Any discrepancies between the two investigators were resolved by discussion with a third investigator (XSG).

Statistical analysis

This meta-analysis was conducted with STATA version 12.0 (StataCorp LP, Texas, USA). P<0.05 was considered as statistically significant. Odds ratios (ORs) with 95% confidence intervals (CIs) were utilized to evaluate the association between CD133 expression and clinicopathological characteristics. The relevant clinicopathological features included tumor grade, lymph node metastasis, tumor size, TNM stage, age, progesterone receptor (PR) status, ER status, and human epidermal growth factor receptor 2 (HER2) status. Hazard ratios (HRs) and 95% CIs of OS were used to evaluate pooled HR. If HR and 95% CI were not reported in the text, then they were calculated from Kaplan-Meier curves, according to the method intro-
CD133 and breast cancer

Results

Search results

The process of study selection is detailed in Figure 1. A total of 1514 records from database searches and 5 records from other sources were identified. After duplicate records were removed, 1167 records were screened by inspection of title and/or abstract. On this basis, 1138 records were excluded, and 29 full-text studies were evaluated for eligibility. Eighteen studies were further excluded for the following reasons: 13 studies provided insufficient data, 3 studies were meeting abstracts, 1 study presented duplicate data, and 1 study was a review. Finally, 11 studies [10-20] were included in the meta-analysis.

Characteristics of included studies

The characteristics of the included studies are shown in Table 1. The included studies were published from 2009 to 2015. The total number of samples was 1447, ranging from 49 to 325 per study. Ten studies [10, 11, 13-20] were in English and one [12] was in Chinese. Seven studies [10, 12-14, 17-19] were performed in Asia, two [11, 16] were conducted in Europe, one [15] was carried out in Oceania and one [20] was conducted in Africa. All studies used IHC to detect CD133 expression, and the percentage of positive CD133 expression varied from 18.8% to 74.4%. All 11 studies [10-20] reported an association between CD133 and clinicopathological features, and 4 studies [13, 14, 17, 18] reported a correlation between CD133 and OS. The NOS scores of the included studies ranged from 6 to 8, indicating that all eligible studies were high quality studies.

Correlation of CD133 expression with clinicopathological factors

The relationship between CD133 expression and 8 clinicopathological factors was investigated. These 8 factors were: tumor grade (G3 vs. G1+G2), lymph node metastasis (positive vs. negative), tumor size (≥2 cm vs. <2 cm), age (≥50 years vs. <50 years), PR status (positive vs. negative), ER status (positive vs. negative), TNM stage (III+IV vs. I+II), and HER2 status (positive vs. negative). As shown in Figure 2 and Table 2, CD133 overexpression was associated with G3 tumor grade (OR=1.82, 95% CI=1.4-2.36, P<0.001), presence of lymph node metastasis (OR=2.21, 95% CI=1.75-2.79, P<0.001), negative PR status (OR=0.62, 95% CI=0.47-0.81, P=0.001), negative ER status (OR=0.4, 95% CI=0.19-0.86, P=0.018), advanced TNM stage (OR=2.74, 95% CI=2.05-3.66, P<0.001), and positive HER2 status (OR=2.00, 95% CI=1.04-3.85, P=0.039). However, there was no significant correlation between CD133 and...
CD133 and breast cancer
Figure 2. Forrest plot of ORs for the relation of CD133 expression with (A) tumor grade, (B) lymph node metastasis, (C) tumor size, (D) age, (E) PR status, (F) ER status, (G) TNM stage, and (H) HER2 status in breast cancer.
CD133 and breast cancer

Table 2. Association between CD133 expression and clinicopathological features in breast cancer

<table>
<thead>
<tr>
<th>Factors</th>
<th>No. of studies</th>
<th>Effects model</th>
<th>OR (95% CI)</th>
<th>p</th>
<th>Heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor grade (G3 vs. G1+G2)</td>
<td>10</td>
<td>Fixed</td>
<td>1.82 (1.4-2.36)</td>
<td>&lt;0.001</td>
<td>18.1</td>
</tr>
<tr>
<td>Lymph node metastasis (positive vs. negative)</td>
<td>10</td>
<td>Fixed</td>
<td>2.21 (1.75-2.79)</td>
<td>&lt;0.001</td>
<td>49.5</td>
</tr>
<tr>
<td>Tumor size (≥2 cm vs. &lt;2 cm)</td>
<td>9</td>
<td>Random</td>
<td>1.59 (0.94-2.67)</td>
<td>0.083</td>
<td>67.3</td>
</tr>
<tr>
<td>Age (≥50 years vs. &lt;50 years)</td>
<td>8</td>
<td>Random</td>
<td>0.84 (0.55-1.27)</td>
<td>0.41</td>
<td>52.8</td>
</tr>
<tr>
<td>PR status (positive vs. negative)</td>
<td>7</td>
<td>Fixed</td>
<td>0.62 (0.47-0.81)</td>
<td>0.001</td>
<td>47.8</td>
</tr>
<tr>
<td>ER status (positive vs. negative)</td>
<td>6</td>
<td>Random</td>
<td>0.4 (0.19-0.86)</td>
<td>0.018</td>
<td>82.8</td>
</tr>
<tr>
<td>TNM stage (III+IV vs. I+II)</td>
<td>6</td>
<td>Fixed</td>
<td>2.74 (2.05-3.66)</td>
<td>&lt;0.001</td>
<td>32.3</td>
</tr>
<tr>
<td>HER2 status (positive vs. negative)</td>
<td>5</td>
<td>Random</td>
<td>2.00 (1.04-3.85)</td>
<td>0.039</td>
<td>66.9</td>
</tr>
</tbody>
</table>

PR: progesterone receptor; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2.

Figure 3. Forrest plot of HR for the relation of CD133 expression with OS in breast cancer.

expression and tumor size (P=0.083) or age (P=0.41).

Relationship between CD133 expression and OS

Four studies [13, 14, 17, 18] investigated the impact of CD133 expression on OS. Since significant heterogeneity was found (I²=58.5%, P=0.065), a random-effect model was used. The meta-analysis results demonstrated that CD133 overexpression was significantly associated with poor OS (HR=2.04, 95% CI=1.32-3.14, P<0.001) (Figure 3).

Publication bias

Begg’s rank correlation test and Egger’s regression test were used to examine potential publication bias in our meta-analysis. The results were P=1 for Begg’s test, and P=0.186 for Egger’s test, for OS analysis (Figure 4). These results showed that there was no evidence of significant publication bias existing in this meta-analysis.

Discussion

Breast cancer is the most common cancer in women. Breast cancer is complex, and patients often have different responses and clinical outcomes following treatment. CD133 expression was found to be correlated with survival outcomes in breast cancer, but the results were inconsistent. In the current study, we extracted relevant data from 11 eligible studies to perform a meta-analysis. The results showed that CD133 expression was associated with a higher tumor grade, occurrence of lymph node metastasis, negative PR status, negative ER status, advanced TNM stage, and positive HER2 status. With respect to the association between CD133 expression and OS, the data showed that CD133 overexpression was an indicator of a poorer OS (HR=2.04, 95% CI=1.32-3.14, P<0.001). Taken together, this meta-analysis demonstrated that CD133 expression is a potential marker for a panel of clinicopathological factors and linked to a poor prognosis for breast cancer.

CD133 is a commonly used cell surface marker of CSCs in a wide spectrum of cancers [4]. CD133 is expressed in normal tissues, including hematopoietic stem and progenitor cells [24], fetal neural stem cells [25], renal stem cells [26], and prostate stem cells [27]. Furthermore, CD133 is also used as a marker
CD133 overexpression was correlated with poor survival outcomes, which was consistent with our results. Furthermore, there has to date been no meta-analysis investigating the prognostic value of CD133 in breast cancer. To the best of our knowledge, this meta-analysis is the first study to comprehensively and systematically evaluate the association between CD133 expression and prognosis in breast cancer.

Several limitations of this meta-analysis also need to be acknowledged. First, the number of studies included and total sample size were relatively small. Furthermore, only 4 studies were included for OS analysis. Although other studies reported the survival information, HR and 95% CI could not be extracted from the available data. Secondly, most studies (7 of 11) were conducted in Asia, which may introduce selection bias.

In summary, this study demonstrated that CD133 overexpression was associated with higher tumor grade, occurrence of lymph node metastasis, negative PR status, negative ER status, advanced TNM stage, positive HER2 status, and poor OS, in breast cancer. CD133 may be considered a useful tool for pathological diagnosis and prognostic prediction in breast cancer. Owing to the aforementioned limitations, further large-scale studies, recruiting populations of various ethnicities, are needed to confirm our results.

Disclosure of conflict of interest

None.

Address correspondence to: Xianshu Gao, Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China. Tel: +86-10-83575239; Fax: +86-10-66551788; E-mail: docorgaots@126.com

Figure 4. (A) Begg’s funnel plot and (B) Egger’s regression asymmetry plot for CD133 overexpression and OS.
References


CD133 and breast cancer


